Genomic Prediction of Multiple Sclerosis Severity: Current Evidence and Clinical Limitations
Multiple sclerosis is a chronic inflammatory and neurodegenerative disease of the central nervous system characterized by substantial heterogeneity in clinical course. Some patients experience limited disability over decades, whereas others progress rapidly toward impaired ambulation, secondary progression, or severe neurological disability. This variability creates a major clinical challenge: physicians must often make early therapeutic decisions without precise knowledge of an individual patient’s future disease trajectory. Although modern disease-modifying therapies can reduce inflammatory activity, reliable biomarkers that predict long-term disability progression remain limited. Genetic information has therefore attracted considerable attention as a potential tool for risk stratification and personalized management.
From Susceptibility Genetics to Severity Genetics
Genetic research in multiple sclerosis has historically focused on disease susceptibility rather than disease severity. More than two hundred loci have been associated with the risk of developing multiple sclerosis, many of which implicate immune pathways. However, susceptibility to disease and progression after disease onset are biologically distinct processes. The discovery of genetic variants associated with severity would be particularly important because it could reveal mechanisms of neurodegeneration, central nervous system resilience, and irreversible disability accumulation. Recent genome-wide association studies proposed several candidate severity variants, including rs10191329A, which was reported as a genome-wide significant variant associated with more severe disability outcomes.
Evaluating rs10191329A in a Real-World Cohort
The study examined whether rs10191329A could predict clinically meaningful outcomes in a large, prospective, real-world cohort of people with multiple sclerosis. The investigators analyzed 1,455 patients from the South Wales Multiple Sclerosis registry, a longitudinal clinical resource established in 1985. This cohort allowed detailed assessment of disease course using physician-recorded Expanded Disability Status Scale scores, age-related multiple sclerosis severity scores, relapse history, disease-modifying treatment exposure, and anatomical localization of relapses. Importantly, the cohort was independent of the original discovery studies, making it suitable for external validation.
Lack of Association With Disability Milestones
The central finding was that rs10191329A did not show a detectable association with long-term multiple sclerosis severity in this cohort. The variant was not associated with age-related multiple sclerosis severity score, age at disease onset, annualized relapse rate, time to major Expanded Disability Status Scale milestones, or conversion to secondary progressive multiple sclerosis. Survival analyses comparing risk-allele carriers with non-carriers similarly failed to demonstrate accelerated progression to EDSS 4, EDSS 6, EDSS 8, or secondary progression. These findings suggest that, although rs10191329A may be biologically interesting, its effect is not sufficiently robust for individual-level prognostication in routine clinical practice.
Relapse Phenotype and Anatomical Localization
The investigators also explored whether rs10191329A might influence earlier inflammatory features of the disease, such as relapse frequency, relapse localization, or recovery after the first demyelinating event. No meaningful differences were observed between genotype groups in annualized relapse rate, time to second clinical relapse, incomplete recovery after disease onset, or anatomical distribution of clinical attacks. This is important because disability in multiple sclerosis may arise through both relapse-associated worsening and progression independent of relapse activity. The absence of association across these domains indicates that rs10191329A is unlikely to exert a clinically visible effect through relapse biology in this cohort.
Other Severity Variants and HLA Findings
Although the main genome-wide significant severity variant was not replicated, the study did support associations for two previously suggestive variants, rs7289446G and rs868824C, with long-term disability-related outcomes. These effects were modest, and their clinical usefulness remains limited. The study also evaluated HLA-DRB1*1501, a well-established multiple sclerosis susceptibility allele. HLA-DRB1*1501 was associated with younger age at onset but not with long-term disability severity. This distinction reinforces the broader concept that genetic determinants of disease onset may differ from genetic determinants of disease progression.
Implications for Precision Medicine in Multiple Sclerosis
The study provides an important cautionary message for genomic medicine in multiple sclerosis. Discovery of severity-associated variants may improve understanding of disease mechanisms, particularly pathways related to neurodegeneration and central nervous system resilience. However, a genetic association identified at the population level does not automatically translate into a clinically useful prognostic test for individual patients. At present, the effect sizes of known multiple sclerosis severity variants appear too small and inconsistent to guide treatment escalation, counseling, or monitoring strategies on their own. Future progress will likely require larger harmonized cohorts, standardized disability measures, integration of imaging and molecular biomarkers, and polygenic models validated across independent populations.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Kreft, K. L., Uzochukwu, E., Loveless, S., Willis, M., Wynford‐Thomas, R., Harding, K. E., ... & Robertson, N. P. (2024). Relevance of multiple sclerosis severity genotype in predicting disease course: a real‐world cohort. Annals of Neurology, 95(3), 459-470.
